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Cancer treatments improve the survival rate of children and adolescents; however chemo- and radiotherapy result in gonadal
damage leading to acute ovarian failure and sterility. Ovarian tissue cryopreservation allows long-term storage of primordial
folliclesandrepresentstheonlypossibilityofpreservingthepotentialfertilityinprepubertalgirls.Theaimofthepresentstudyisto
describe our experience in ovarian tissue cryopreservation in 45 pediatric patients. The number of follicles per square millimeter
of the overall section area and follicle quality were evaluated histologically. A strong negative correlation was found between
age and follicular density in patients both prior to and after chemotherapy (P<0.0001). Damage in follicular quality, that
is, increased oocyte vacuolization and detachment of the oocyte from granulosa cells, was found after chemotherapy. Ovarian
tissue cryopreservation, preferably performed before initiation of chemotherapy, should be oﬀered to pediatric patients, including
prepubertal girls, at risk of sterility.
1.Introduction
The survival rate of children and adolescents with cancer
has increased markedly over the past 30 years as a result
of advances in supportive care and changes in cancer ther-
apies. The use of cancer multimodal therapy (e.g., surgery,
radiotherapy, and intensive multiagent chemotherapy) is
now routine in the treatment of children with neoplastic
disease. However many children treated for cancer suﬀer
from side-eﬀects of curative chemo- and radiotherapy,
such as the risk of Acute Ovarian Failure (AOF) or early
menopause, then sterility [1]. Gonadal damage results in a
development arrest of secondary sexual characteristics that
prevent the attainment of sexual maturity. As the majority
of women who survive cancer in childhood expect a normal
reproductive life span, an early loss of fertility can seriously
harm their quality of life.
The level of ovarian damage varies according to the can-
cer treatment protocol: ovarian integrity is aﬀected by the
type of chemotherapeutic agent, the cumulative dose of
chemotherapeutic agents, treatment duration, and total
dosage eﬀect. In general alkylating agents such as cyclophos-
phamide are associated with the highest risk of infertility [2–
5]. Ovarian failure has also been reported in patients treated
with other agents such as cisplatin and vinca alkaloids. Of
the multiagent treatment protocols, the adriamycin (dox-
orubicin), bleomycin, vinblastine, and dacarbazine (ABVD)
combination is considered less cytotoxic than other pro-
tocols. Furthermore, the prebone marrow transplantation
(BMT) conditioning protocol of busulfan and cyclophos-
phamide has been found to lead to high rates of sterilization,
whereas high-dose melfalan seems to be safer [2].
Previousstudiesindicatethatradiationaﬀectstheovaries
and the degree of impairment depends on the radiation
dose, fractionation schedule, and radiation ﬁeld. Doses as
low as 400–600cGy in adults and 1000–2000cGy in children
have been noted to decrease ovarian function [6]. The risk
is higher with increasing doses of radiation. Radiotoxicity
appears to be higher when radiation is given as a single
dose as opposed to fractionated. Irradiation to abdominal,
pelvic, or spinal regions is associated with increased risk for
AOF [7]. However, even scattered radiation, not directed2 Obstetrics and Gynecology International
speciﬁcally to the pelvis or abdomen, can cause ovarian
damage. Patients treated with total body irradiation before
BMT together with high doses of chemotherapeutic agents
are very likely to have severe ovarian dysfunction [2].
The most well-established options for female adult fer-
tility preservation are embryo and oocyte cryopreservation.
Unfortunately, in the pediatric setting embryo cryopreser-
vation is inappropriate and ovarian tissue cryopreservation
maybe an alternative option for fertility preservation in
these patients: with ovarian tissue freezing, no ovarian
stimulation is needed and ovarian tissue can be harvested
laparoscopicallywithoutanypreparation.Furthermoreovar-
ian tissue cryopreservation has the greatest fertility potential
in children since they have a high number of primordial
follicles [4, 7–15].
After thawing, cryopreserved ovarian tissue can be
grafted into its normal anatomical position or into a
heterotopic site. Alternatively the thawed tissue can be
placed in culture with the aim to achieve antral follicle
development and to avoid the risk of reimplantation of
malignant cells [16]. However this option has not so far
progressed suﬃciently to be a therapeutic possibility [12].
Untiltodayallpregnanciesobtainedaftertransplantation
of frozen-thawed ovarian cortex were observed in adult
patients at the time of harvesting; however there is no
reason to doubt the capacity of prepubertal ovarian cortex
to develop and function correctly after reimplantation [14].
Animal studies have demonstrated that puberty and cyclic
hormonal activity can be restored by reimplantation of
fresh and frozen–thawed prepubertal ovarian tissue in both
prepubertal and adult mice [17, 18]. In humans only one
experience has been reported by Andersen (data shown to
the ESHRE Campus Symposium, Fertility Preservation in
Cancer, Bologna, 2010). The patient was aﬀected by Ewing
Sarcoma at the age of 9 years, and her ovarian tissue was
cryopreserved before receiving chemo- and radiotherapy.
After cancer treatment, the patient presented clinical and
biological Premature Ovarian Failure (POF) and, at the
age of 13, she underwent reimplantation of cryopreserved
ovarian tissue. One year later, the patient had her ﬁrst
menstrual cycle and evident signs of pubertal development.
However, the uterus of the patient did not grow to adult
size, perhaps because the pelvis had received high doses
of irradiation. It is well known that pelvic radiotherapy
decreasesuterinebloodﬂowandreducesuterinevolumeand
endometrial thickness [3, 4, 19].
Thepurpose ofthispaperistodescribe ourexperiencein
ovariantissuecryopreservationinpediatricpatientsfocusing
on the clinical characteristics of the patients, the technical
procedures, and strategies used to harvest and preserve the
tissue. In adolescent patients, the opportunity to preserve
their fertility enabling a future normal life is a psychological
support allowing the patients to overcome the diﬃculties
that the disease entails.
2.MaterialsandMethods
2.1. Subjects. From January 1999 to August 2011, 51 pediat-
ric patients with malignant and benign diseases approached
the Gynecology and Reproductive Medicine Unit, Depart-
ment of Obstetrics and Gynecology, S. Orsola-Malpighi
Hospital, Bologna, for consultation about the possibility of
ovarian tissue cryopreservation. The ovarian tissue of 45
pediatric patients, including pre-and postmenarcheal girls,
was collected and cryopreserved. Parents of the patients gave
their consent for both laparoscopy and cryopreservation
of ovarian tissue. Ovarian tissue cryopreservation was not
carried out for six patients: in two cases patients did not ﬁt
the inclusion criteria; in two cases parents refused because
the procedure was too new or they did not want their
daughter to be subject to further surgery; in the last two
cases the patients suﬀered from Turner Syndrome with very
small ovaries and a menopausal value of FSH, so, given the
possibility of cryopreservation of few follicles, their parents
refused consent.
At our centre, the exclusion criteria for ovarian tissue
cryopreservation included patients positive for Hepatitis B
Virus (HBV), Hepatitis C Virus (HCV), Human Immunode-
ﬁciency Virus (HIV), or Treponema Pallidum (TP); patients
with ovarian cancers; and patients who had contraindica-
tions for surgery. Regarding patients with leukaemia could
be removed and cryopreserved in the hope that in vitro
maturation of the oocytes will be possible in the future [3].
As listed in Table 1, the majority of patients sent to our
centre were cancer patients (38 of 45); others were aﬀected
by primary or genetic bone marrow disorders (6 of 45)
and autoimmune disorders (one of 45). Within the cancer
patients, more than half (23 of 38) had completed one or
more cycles of chemotherapy before the collection of ovarian
tissue (Table 1). According to the Karnofsky Performance
Status Scale Index, the patients enrolled in the study reached
over 90% in the criteria scale.
Ovarian tissue cryopreservation was carried out within
a maximum of 20–30 days from the last chemotherapy
cycle, while within 10–15 days in patients not undergoing
chemotherapy before ovarian tissue recovery. The ovarian
preservation procedure was not associated with any delay in
the commencement of anticancer treatment.
2.2. Surgical Procedure. Ovarian tissue was collected at our
department by laparoscopy. In all cases laparoscopy was
carried out as a day surgery procedure under general anes-
thesia. A carbon dioxide pneumoperitoneum at a pressure
of 10mmHg was created via a Verres needle inserted into
the peritoneal cavity through an umbilical incision. A three-
port laparoscopy was performed. The primary 5mm port
was inserted through the umbilicus for the telescope; two
secondary 3mm or 5mm ports were inserted to the left
and the right, respectively, lower quadrants at the same level
lateral to the rectus sheath. Ovarian tissue was removed
with scissors proceeding along the connecting line between
two atraumatic graspers positioned in the ovary just above
the infundibulopelvic and utero-ovarian ligaments ﬁrst on
the left and then on the right. Each ovarian fragment
was placed in an Endobag (Cook Medical) and retrieved
through the umbilical 5mm port to avoid tissue damage.
The harvested tissue was then transferred to the laboratory
for immediate cryopreservation. In the majority of cases,Obstetrics and Gynecology International 3
Table 1: Subjects.
Pathology No. patientsa
No. patients
underwent
chemotherapyb
Pathology No. patientsa
No. patients
underwent
chemotherapyb
Acute lymphoblastic
leukaemia 5 5 Synovial sarcoma 1 1
Acute myeloide leukaemia 2 2 Ewing sarcoma 7 1
Hodgkin lymphoma 16 10 Myelodisplasia 1
Non-Hodgkin lymphoma 1 Bone marrow aplasia 2
Wilms tumor 3 2 Systemic lupus erythematosus 1
Peripheral
neuroectodermal tumor
(PNET)
1 1 Thalassemia major 2
Mixoide tumor 1 Medulloblastoma 1 1
Shwachman syndrome 1
aTotal subject number enrolled in the study.
bSubject number underwent chemotherapy beforesurgery.
there was negligible bleeding of the ovaries; haemostasis was
carried out by bipolar current. The port sites were closed
using 4–0 resorbable (Biosyn) sutures. The median duration
of this technique was 30 minutes (range: 15–45min). All
patients were discharged on the day of surgery or at most
the day after, with the discomfort experienced being no
greater than after diagnostic laparoscopy. No complications
occurred due to anesthesia or surgery in any patient.
Forty-three patients underwent laparoscopic harvesting
of ovarian tissue from both ovaries, while in two patients the
ovarian tissue was harvested from only one ovary because
the other ovary was too small (patient with Wilms Tumor)
and in the other case unilateral ovariectomy was performed
(patient with Hodgkin Lymphoma). The amount of ovarian
tissue removed was subordinated to the anticancer treatment
protocol and to the size of the ovaries: in premenarcheal
patients, due to the small size of the ovary and a high density
of primordial follicles, the biopsy was smaller compared to
the postmenarcheal ones.
2.3. Ovarian Transposition. When pelvic radiotherapy is
indicated, ovarian transposition can be performed in order
to displace the ovaries away from the radiation ﬁeld [3–
5, 20]. In our experience, we reported a combined approach
of ovarian tissue cryopreservation and ovarian transposition
in four patients (n = 19, Table 2; n = 9, 10 and
17, Table 3). In these cases the laparoscopy was carried
out as a standard procedure. After ovarian tissue removal
for immediate cryopreservation, the residual ovaries were
temporarily transposed to the lower anterolateral abdom-
inal wall without transection of the ovarian ligament and
mesovarium. In particular, they were ﬁxed intracorporeally
to the peritoneum close to the ipsilateral round ligament
of the uterus, using one 2–0 resorbable braided (Vicryl)
continuous suture [21]. Ovarian transposition induces no
particular injuries on the ovary per se, or to the blood supply
vessels, with no adhesions and disruption of anatomical
relationships, indicating that it may be a valid strategy for
the preservation of ovarian function [21].
2.4. Cryopreservation Procedure of Ovarian Tissue. The cry-
opreservation protocol used by our group was approved
by the Ethics Committee of S. Orsola-Malpighi Hospital
(Clinical trial 74/2001/0 approved on 13/02/2002).
After biopsy, the ovarian tissue was placed in Dulbecco’s
phosphate-buﬀeredsolution(PBS)(Gibco,LifeTechnologies
LTD, Paisley, Scotland) with 10% human serum added
(HS was provided by the Transfusion Centre of S. Orsola-
Malpighi Hospital) and cut into pieces (mean size 1 × 0.3 ×
0.1cm) using a scalpel. The mean number of pieces obtained
was 23.1 ± 6.8 (mean ± SE) in premenarcheal patients and
27.6 ± 2.9 (mean ± SE) in postmenarcheal patients. One
or two pieces (1–3mm) from each ovarian sample were
immediately ﬁxed for histological analysis. The remaining
tissue was maintained in PBS + 10% HS solution until
cryopreservation. Samples were cryopreserved using a slow-
freezing/rapid-thawing protocol, according to Fabbri et al.
[22]. At the end of the cooling program, the cryovials were
transferred into liquid nitrogen and stored until thawing.
For each patient, a cryopreserved sample from each
ovary was thawed after one month and ﬁxed for histological
analysis in order to evaluate the preservation of cortical
tissue.
2.5. Histological Analysis. Fresh and frozen/thawed tissue
samples were ﬁxed in a freshly prepared solution of 2.5%
glutaraldehyde in 0.1mol/L sodium cacodylate buﬀer, pH
7.4, overnight at 4◦C. After osmium tetroxide postﬁxation
and alcohol dehydration, the samples were embedded in
Araldite epoxy resin (Fluka, Buchs, Switzerland) and then
sectioned with an ultramicrotome (Ultracut; Reichert, Wien,
Austria). For each sample one 0.5µm thick section out of
every 50 was collected and stained with toluidine blue for
light microscopy (LM) examination (Leitz Diaplan light
microscope equipped with a CCD JVC video camera).
Semithin sections were examined, double blind by two
trained pathologists, to (i) identify and count follicles, (ii)
establish the number of damaged follicles, and (iii) assess
follicular density, expressed as the number of follicles per4 Obstetrics and Gynecology International
Table 2: Characteristics of the pre-chemotherapy patients who had ovarian tissue cryopreservation.
No. Pathology Age (months) D/mm2
(RO) D/mm2 (LO) Cryopreserved
fragments No.
1 Wilms tumor 53 49.89 — 63
2 Shwachmann syndrome 118 58.83 24.05 10
3 Ewing sarcoma 78 36.92 39.04 10
4 Ewing sarcoma 120 64.02 102.77 15
5 Hodgkin lymphoma 161 11.51 16.53 23
6 Hodgkin lymphoma 177 31.8 13.59 44
7 Hodgkin lymphoma 182 11.26 1.00 14
8 Hodgkin lymphoma 195 90.80 44.28 10
9 Non-Hodgkin lymphoma 205 1.92 1.74 9
10 Hodgkin lymphoma 206 12.18 15.64 14
11 Ewing sarcoma 144 159.24 26.30 11
12 Ewing sarcoma 173 0.69 1.58 16
13 Ewing sarcoma 184 18.41 15.45 23
14 Ewing sarcoma 190 3.20 11.84 21
15 Bone marrow aplasia 152 14.68 15.12 45
16 Bone marrow aplasia 160 14.47 10.37 38
17 Myelodisplasia 152 4.07 11.26 17
18 Mixoide tumor 203 15.47 8.01 16
19 Thalassemia major 180 9.98 17.80 22
20 Thalassemia major 193 2.58 6.96 33
21 Hodgkin lymphoma 214 18.24 13.87 12
22 Systemic lupus
Erythematosus 198 1.87 1.66 33
No. 1–4 premenarcheal patients, No. 5–22 postmenarcheal patients.
D/mm2:f o l l i c l ed e n s i t yp e rm m 2.
RO: right ovary; LO: left ovary.
square millimeter of the overall section area. Measurements
were performed on digitalized images using ImageProPlus
software.
Semithin stained sections were initially observed at 10x
to determine whether tissue was appropriate for histological
examination: artefacts, erroneous sampling, presence or
absence of follicles, and pathological involvement of ovarian
tissuewererecorded.Sectionswerethenobservedatmedium
(25x) and high magniﬁcation (40x). Follicles were counted
and classiﬁed as resting type (primordial, intermediary
primordial follicles, and small primary), growing type (large
primary, secondary, preantral, antral), and atretic type,
according to Gougeon classiﬁcation [23]. At 40x the quality
of follicles was determined; follicles containing oocytes with
empty appearance, large cytoplasmic vacuoles, dark and
granular cytoplasm, hyperchromatic nuclear staining, and
detachment of the oocyte from the granulosa cells were
considered degenerated.
2.6. Hormone Assays. Blood samples were analyzed for FSH,
LH, Estradiol, Estrone, Prolactin, Testosterone, and 17-Hy-
droxyprogesterone one or two days before laparoscopy.
2.7. Follow-Up. Follow-up was performed six months after
theendoftherapy,andtheneveryyear,usingultrasoundand
hormonal tests.
2.8. Statistical Analysis. We studied the follicular density of
the pre- and post-chemotherapy groups and, within each
group, the follicular density of pre and postmenarcheal
patients. The relationship between age and follicular density
was evaluated using a linear regression model. Follicular
density value used for statistical analysis was obtained by
averaging the follicular densities of the left and right ovary.
Results were statistically analysed by unpaired t-test. A value
of P<0.05 was accepted as signiﬁcantly diﬀerent.
3. Results and Discussion
Ovarian tissue was collected and cryopreserved from 45
pediatric patients aged 160.9 ± 6.9 months (mean ± SE).
Patients were grouped into two categories: pre-
chemotherapy patients (n = 22) aged 53–214 months
(161.4 ± 8.9, mean ± SE) (Table 2) and post-chemotherapy
patients (n = 23) aged 19–215 months (156.4 ± 10.6,
mean ± SE) (Table 3). The speciﬁc chemotherapy regimen
for each patient in relationship to the individual disease is
g i v e ni nT a b l e3.
In both groups, menarcheal age was 150 ± 3.8 months
(mean ± SE). In the pre-chemotherapy group 80% of
patients had regular menstrual cycles and normal ﬂow,
whereas 20% had slightly irregular menstrual cycles of up to
35 days. In post-chemotherapy patients, it was not possibleObstetrics and Gynecology International 5
Table 3: Characteristics of the post-chemotherapy patients who had ovarian tissue cryopreservation.
No. Pathology Chemotherapy Age
(months)
D/mm2
(RO) D/mm2(LO) Cryopreserved fragments No.
1 Wilms tumor Vincristine, AMD 19 268.63 49.69 4
2 Wilms tumor Vincristine, AMD 48 — — 1
3 Acute myeloide leukaemia ICE, AVE, HAM, ARA-C 70 112.84 56.23 19
4 Acute lymphoblastic
leukaemia
Vincristina,
cyclophosphamide,
methotrexate
91 40.61 92.09 24
5 Acute lymphoblastic
leukaemia AIEOP 9502 170 12.03 22.62 67
6 Hodgkin lymphoma COPP/ABV 81 59.38 — 10
7 Hodgkin lymphoma COPP/ABV + IEP-OPPA 134 9.96 11.05 31
8 Hodgkin lymphoma COPP/ABV 131 7.18 13.90 42
9 Hodgkin Lymphoma ABVD 150 12.64 29.98 13
10 Hodgkin Lymphoma COPP/ABV 165 5.66 8.87 55
11 Hodgkin lymphoma COPP/ABV 166 19.19 43.34 14
12 Hodgkin lymphoma COPP/ABV 175 5.55 10.81 13
13 Hodgkin lymphoma IEP/IOPPA 177 30.33 31.57 21
14 Hodgkin lymphoma COPP/ABV 197 6.80 11.99 8
15 Hodgkin lymphoma COPP/ABV 215 5.08 7.67 49
16 Synovial sarcoma IFO, AMD 154 15.12 14.95 47
17 Ewing sarcoma ISG/SSG IV 170 8.04 7.82 71
18 Acute myeloide leukaemia Idarubicin, etoposide,
citrabina 180 3.67 4.56 20
19 Acute lymphoblastic
leukaemia
Vincristine, daunomycin,
predmisone 183 9.61 10.45 12
20 Acute lymphoblastic
leukaemia Unspeciﬁed 192 19.37 12.18 33
21 Acute lymphoblastic
leukaemia
Vincristine,
cyclophosphamide,
methotrexate
209 12.02 11.36 53
22 Medulloblastoma Vincristine 199 9.85 10.19 25
23 Peripheral
neuroectodermal tumor
IFO, etoposide, thiotepa,
adriamycin melphalan 212 0 0 61
No. 1–7 premenarcheal patients; No. 8–23 postmenarcheal patients.
D/mm2:f o l l i c l ed e n s i t yp e rm m 2.
RO: right ovary; LO: left ovary.
AMD: Actinomycin D; ICE: Idarubicin, Etoposide, Cytarabin; HAM: Mitoxantrone; ARA-C: Citosinarabinoside; AIEOP9502.
Protocol: Vincristine, Daunomycin, Predmisone, Asparaginase, Cyclophosphamide, 6-Mercaptopurine, Methotrexate, Adriamycin,
Dexamethasone, Cyclophosphamide, Citosinarabinoside, 6-Thioguanina; COPP/ABV: Vincristine, Procarbazine,
Cyclophosphamide, Prednisone, Adriamycin, Vinblastine, Bleomycin; IEP-OPPA: Ifofosfamide, Etoposide, Prednisone, Vincristine,
Procarbazine, Prednisone, Adriamycin; ABVD: Adriamycin, Bleomycin, Vincristine, Doxorubicin; IFO: Ifofosfamide; ISG/SSG IV.
Protocol: Vincristine, Adriamycin, Ifosfamide, Cyclophosphamide, Etoposide.
to evaluate menstrual cycles because they had been treated
with pills or GnRH analogues.
A total of 5749 follicles from pre-chemotherapy patients
and 2684 follicles from post-chemotherapy patients were
analyzed; in both series LM showed that 99% of follicles
were of the resting type and 1% distributed among primary,
secondary, and preantral follicles. In one patient (n = 2,
Table 3), the ovarian biopsy was too small and the entire
cortex was cryopreserved. In all patients, LM on serial
sections did not identify any neoplastic cells. Damaged
follicles were observed in 26.1 ± 4.2% (mean ± S E )o ft h e
pre-chemotherapy group and in 34.3 ± 5.3% (mean ± SE)
of the post-chemotherapy group (NS). The main alterations
of damaged follicles observed were oocyte vacuolization and
detachment of the oocyte from the granulosa cells. The high
percentageoffollicledamageinthepre-chemotherapygroup
could be attributed to the large number of patients with
Hodgkin Lymphoma enrolled in this study. As shown in our
study(Fabbrietal.,2011)[24],HodgkinLymphomapatients
have a high frequency of vacuolization in resting oocytes
(73.7%) before chemotherapy that positively correlates with
disease stage, whereas in the control group only the 5.7%6 Obstetrics and Gynecology International
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Figure 1: Correlation between age and follicular density in pre-
chemotherapy and post-chemotherapy groups.
of the oocytes showed microvacuolar changes and large-
sized vacuoles were never seen. In the post-chemotherapy
group,thehighestpercentageoffolliculardamageconﬁrmed
a previous study demonstrating the gonadotoxic eﬀect of
chemotherapy on follicular quality [2, 25]. However the
lack of signiﬁcant diﬀerence in the percentage of damaged
follicles between pre- and post-chemotherapy groups could
be due to the great variability of chemotherapic protocol
and to the low number of cycles performed in this group of
patients. It is therefore possible that chemotherapy has not
yet fully demonstrated its real injury to the ovary.
In agreement with literature [10, 26], we found an
age-dependent decline in follicular density in pediatric
patients. In the pre-chemotherapy group as well as in the
post-chemotherapy group, the follicular density showed a
statistically negative correlation dependent on patient age
(y =− 0.378x +8 7 .124, R2 = 0.354, P<0.0001; y =
−0.637x + 126.63, R2 = 0.776; P<0.0001) (Figure 1). Fol-
licular density results were higher in premenarcheal patients
than in the postmenarcheal in the pre-chemotherapy group
(53.4 ± 10.3 versus 18.2 ± 5.6, P<0.05; mean ± SE) as
well as in the post-chemotherapy group (66.1 ± 22 versus
12.4 ± 2.1, P<0.001; mean ± SE) (Figure 2).
Follicular density results were slightly higher in the post-
chemotherapy group than in the pre-chemotherapy group
(24.6 ± 5.7 versus 27.1 ± 7.8, NS; mean ± SE) (Figure 3).
This ﬁnding may be due to the inclusion of the youngest
patient (n = 1, Table 3 19 months) with the highest follicular
density (159.16) in the post-chemotherapy group.
Hormone levels of pre-chemotherapy patients were
within the reference range of our laboratory for age
and phase of menstrual cycle. Hormone levels of post-
chemotherapy patients were not considerable because these
patients were receiving pills or GnRH analogue treatment to
protect the ovarian function.
Median follow-up time was 30 months (range 10–50
months). Thirty-six of the girls are still alive. Nine patients
died of the primary pathology during the study period: three
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of these patients suﬀered from Acute Leukaemia, two from
Hodgkin’s Lymphoma, one from Wilms Tumor, one from
PNET, one from Thalassemia Major, and one from Synovial
Sarcoma. To date we have not received any request for
ovarian tissue reimplantation because most of the patients
are very young, many are still undergoing treatments, and
others do not currently need or desire motherhood.
Ovarian tissue cryopreservation oﬀers great promise
for fertility preservation among young patients aﬀected by
cancer and represents the only option for prepubertal girls.
The human ovary has a ﬁxed number of primordial follicles
which progressively decrease with increasing age in a biexpo-
nential fashion, culminating in the menopause at around 50
years of age. Both chemotherapy and radiotherapy quicken
follicle depletion leading to premature menopause [27].
Ovarian tissue cryopreservation is particularly important in
children because they have a high number of primordial and
primary follicles that are particularly resistant to freezing
and thawing protocols. A further beneﬁt for pediatric
patients is the possibility of using the cryopreserved ovarianObstetrics and Gynecology International 7
tissue after a longer period than with adult patients. The
probability of restoring fertility is related to the number
and quality of primordial follicles in the ovarian cortical
transplanted. Ovarian tissue cryopreservation also allows the
restoration of steroidogenic function and promotes physio-
logical development, puberty induction, and consequently
the uterus growth. The puberty induction should be the
main aim of ovarian tissue cryopreservation in prepubertal
patients; alternatively these patients may undergo hormone
replacement therapy and use the frozen ovarian tissue only if
thereisdesireformotherhood.Theﬁnaldecisioncanonlybe
made together by the oncologists, specialists in reproductive
medicine and the parents who must make decisions based on
the assumed future wishes of the girl.
To date many authors have written about availability,
feasibility, safety, and eﬃciency of ovarian tissue cryopreser-
vation in pediatric patients. Jadoul et al. [14]p e r f o r m e d
ovarian cryopreservation in 58 girls under 16 years of age
in order to validate the technique, concluding that ovarian
cortex cryopreservation is feasible and as safe as comparable
operative procedure in children. Poirot et al. [10]c o n d u c t e d
a study to describe their experience of ovarian tissue cryop-
reservation in 49 prepubertal females before chemotherapy,
focusing on the feasibility of the technique and speciﬁc
features of the procedure for prepubertal children. They
concludedthatthisprocedurecouldbesystematicallyoﬀered
to prepubertal girls at risk of sterility due to gonadotoxic
treatment. Revel et al. [13]p e r f o r m e das t u d yi nw h i c ha l l
patients undergoing ovarian cryopreservation were subject
to integrated oocyte aspiration from antral follicle of the
tissue, followed by In Vitro Maturation and oocyte cryop-
reservation as an additional fertility preservation strategy.
They investigated the success of this procedure in 19
patients, aged 5–20 years, and retrieved oocytes from even
the youngest patients (5- and 8-year-old girls). They con-
cluded that patients undergoing ovarian cryopreservation
could beneﬁt from supplementary oocyte aspiration from
the cortex. However being an experimental approach, it
should be cautiously presented to young patients. Oktay
and Oktem [7] reported the long-term follow-up and
their experience with ovarian tissue cryopreservation in a
series of 26 patients aged between 4 and 21 years of age,
between 1999 and 2008. Their analysis suggested that tissue
freezing in patients with diﬀerent diseases and ages could be
performed without signiﬁcant risk. The study also revealed
that the utilization rate of banked tissue is low, because the
technology is only a decade old and because most patients
undergoing ovarian cryopreservation are young and many
arestillundergoingtreatment.Weintraubetal.[11]r epo rt ed
their experience on an ovarian cortex bank and presented
a multidisciplinary discussion of the risks and beneﬁts
associated with ovarian tissue cryopreservation, suggesting
that all girls about to receive treatment with a high risk
of infertility be oﬀered consultation on the possibility of
performing ovarian cryopreservation. Anderson et al. [12]
reviewed the advantages and disadvantages of ovarian tissue
cryopreservation in the context of their experience of 36
women, 15 of whom were aged 16 or less. They highlighted
the uncertainties surrounding the development of criteria
for patient selection, the eﬀects of chemotherapy on fertility,
the most appropriate surgical techniques, and how many
women will return to use their stored tissue. According to
Borgstrom et al. [28], even patients with Turner Syndrome
may beneﬁt from cryopreservation as long as they exhibit
essential characteristics for the recovering of follicles in the
ovaries. In this study the authors involved 57 girls aged
8–19,8 with Turner Syndrome in order to evaluate which
girls might beneﬁt from ovarian tissue freezing for fertility
preservation. They established ﬁve characteristics as being
important for ﬁnding follicles in the ovaries of girls with
Turner Syndrome: karyotype, low FSH levels, high AMH,
spontaneous menarche, and spontaneous onset of puberty.
4. Conclusions
This study reports on a large number of pediatric girls
undergoing ovarian tissue cryopreservation to preserve fer-
tility. Our data show a high correlation between follicular
density and age, and a decrease in follicular quality after
chemotherapy. In light of these results and those reported
in literature, the orientation of our group is in favour of
ovarian tissue cryopreservation in pediatric patients because
the procedure has a high potential of maintaining endocrine
function and preserving fertility. It is well known that
the optimal timing of ovarian cryopreservation is before
sterilizing treatment. However, the live births obtained in
adults after transplantation of ovarian tissue cryopreserved
after chemotherapy and the high number of healthy follicles
found in histological sections of tissue after chemotherapy
in pediatric patients indicate that ovarian tissue cryop-
reservation could be oﬀered after chemotherapy to young
girls. In addition, the indication for fertility preservation in
children can be extended to patients genetically predisposed
to premature ovarian failure (e.g., Turner Syndrome), with
acceptable results. Although no births have yet resulted from
freeze-thawing of prepubertal ovarian cortex, expectations
of this approach are encouraging, considering the high
follicular pools of these patients.
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